Clinical trial
Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the…
NCT00431041 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00431041 |
|---|---|
| Title | Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR) |
| Official title | VECTOR: A Randomized Double-blind Study to Assess the Safety and Efficacy of Solifenacin (Vesicare®) in Comparison to Oxybutynin for Overactive Bladder Patients |
| Acronym | VECTOR |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | Astellas Pharma Canada, Inc. Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Overactive Bladder |
| Intervention type | Drug |
| Interventions | solifenacin, oxybutynin immediate release |
| Enrollment | 132 |
| Start date | Dec 1, 2006 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Feb 2, 2007 |
| Last update posted | Jun 8, 2010 |
| Countries | Canada |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: